Published on 22/12/2025
Local Manufacturing Obligations for Investigational Medicinal Products in China
Introduction
Investigational Medicinal Products (IMPs) are the cornerstone of clinical trials, requiring rigorous controls to ensure safety, quality, and compliance. In China, sponsors must navigate specific local manufacturing requirements governed by the National Medical Products Administration (NMPA). These rules dictate how IMPs must be produced, labeled, packaged, and distributed within the country. Unlike in some regions where IMPs can be imported without local production, China emphasizes domestic manufacturing to ensure quality oversight and data integrity. This article explores the regulatory framework, operational challenges, and best practices for sponsors managing IMPs in Chinese clinical trials.
Background and Regulatory Framework
Legal Foundations
The 2019 Drug Administration Law and NMPA Good Manufacturing Practice (GMP) standards form the foundation of IMP regulation in China. All IMPs used in trials must be manufactured in facilities holding a valid GMP certificate issued by the NMPA. Sponsors must demonstrate that manufacturing processes meet both Chinese GMP standards and International Council for Harmonisation (ICH) guidelines.
Domestic vs. Imported IMPs
While multinational sponsors often prefer to import IMPs, the NMPA requires justification for foreign production and may request local manufacturing for certain categories, especially biologics and sensitive
Case Example: Oncology IMP Production
A global oncology sponsor was required by the NMPA to manufacture Phase III IMP batches in a certified domestic facility to ensure batch release and quality testing under local oversight. This requirement helped regulators verify data integrity before global submissions.
Core Clinical Trial Insights
GMP Compliance Requirements
All IMPs manufactured locally must comply with GMP standards, including validated processes, cleanroom environments, and robust quality management systems. Inspections by the NMPA focus on documentation, batch records, and stability testing.
Site Accreditation and Licensing
Manufacturing sites must hold a current NMPA GMP certificate. Sponsors must confirm site accreditation before submitting trial applications. Non-accredited sites cannot produce IMPs, and CROs supporting local manufacturing must also comply with NMPA audits.
Labeling and Packaging Rules
IMPs must be labeled in Mandarin and include trial-specific information such as protocol number, batch number, storage conditions, and “For Clinical Trial Use Only” statements. Packaging must comply with Good Supply Practice (GSP) standards to ensure traceability and security.
Batch Release Obligations
Each IMP batch manufactured in China requires formal release by a Qualified Person (QP) or designated quality control officer. Batch release documentation must be submitted to the NMPA, and any deviations must be justified and corrected through CAPA.
Supply Chain Management
Distribution of IMPs must follow strict GSP protocols, including temperature monitoring, secure storage, and detailed chain-of-custody records. Cold-chain requirements for biologics demand specialized infrastructure and vendor oversight.
Integration with Global Trials
When IMPs are manufactured locally but included in multinational trials, sponsors must ensure consistency with global production standards. Harmonized batch testing and bridging studies may be required to confirm comparability between domestic and international batches.
Inspection Trends and Common Findings
NMPA inspections often highlight deficiencies in GMP documentation, inadequate stability testing, and incomplete training records. Sponsors must proactively audit manufacturing partners to prevent inspection findings that could delay trial approvals.
Best Practices & Preventive Measures
Sponsors should:
– Select NMPA-accredited GMP facilities early in planning.
– Validate manufacturing and packaging processes before trial initiation.
– Ensure all labeling complies with Mandarin-language requirements.
– Audit local manufacturers and CROs regularly for compliance.
– Maintain complete batch records and stability data.
– Train staff in GMP, GSP, and clinical supply chain requirements.
These measures safeguard compliance and ensure uninterrupted IMP supply.
Scientific & Regulatory Evidence
China’s local IMP requirements align with ICH E6(R2) GCP, ICH Q7 GMP for APIs, and WHO guidelines for investigational product management. Evidence from NMPA inspections shows that local oversight strengthens data credibility and enhances global regulatory acceptance of Chinese trial results.
Special Considerations
Advanced therapies such as cell and gene therapies face stricter requirements, often necessitating local GMP-certified facilities with specialized containment. Pediatric and rare disease IMPs may require small-batch, customized production, further complicating compliance.
When Sponsors Should Seek Regulatory Advice
Sponsors should seek NMPA advice when planning IMP strategies involving biologics, cell/gene therapies, or imported IMPs requiring bridging studies. Early consultation helps align expectations on manufacturing location, quality standards, and documentation requirements.
Case Studies
Case Study 1: Biologic IMP Local Production
A multinational sponsor conducting a biologic trial was required to produce clinical batches in a Chinese GMP-certified facility. This ensured quality oversight by the NMPA and facilitated faster approval timelines for domestic patients.
Case Study 2: Rare Disease IMP Packaging
A rare disease sponsor faced labeling non-compliance issues when packaging failed to include Mandarin instructions. After corrective action and re-labeling, the trial resumed without further delays, underscoring the importance of early quality checks.
FAQs
1. Are all IMPs required to be manufactured locally in China?
No, but the NMPA may require local production for biologics and sensitive therapies. Imported IMPs must meet strict import licensing and GMP standards.
2. What labeling requirements apply to IMPs in China?
Labels must be in Mandarin and include protocol number, batch details, storage conditions, and “For Clinical Trial Use Only.”
3. Who approves IMP batches for clinical use?
Each batch must be released by a Qualified Person or designated quality officer under NMPA oversight, with full batch documentation.
4. How does China ensure IMP supply chain integrity?
Through GSP requirements covering storage, temperature monitoring, secure transportation, and chain-of-custody documentation.
5. What common inspection findings occur in local IMP production?
Findings often involve incomplete GMP records, stability data gaps, inadequate staff training, and improper labeling or packaging.
6. How are locally manufactured IMPs integrated into global trials?
Through harmonized manufacturing standards, bridging studies, and alignment with ICH guidelines to ensure comparability across regions.
Conclusion & Call-to-Action
China’s local manufacturing requirements for IMPs are central to ensuring trial integrity and regulatory compliance. Sponsors must plan early, select accredited facilities, and maintain rigorous GMP and GSP standards. By aligning local production with global requirements, organizations can accelerate trial approvals, protect patient safety, and enhance acceptance of Chinese trial data worldwide. Sponsors should view local manufacturing not as a barrier but as a strategic advantage in clinical development.